The New England Journal of Medicine

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody ...
The New England Journal of Medicine

Biologic Therapies for Severe Asthma

Dupilumab (interleukin-4Rα; antibody binds to interleukin-4Rα, inhibiting interleukin-4 and interleukin-13 signaling in hematopoietic cells [e.g., B cells, CD4+ helper T cells, and eosinophils], ...
BioWorld

GSK’s ultra-long-acting IL-5 antibody hits endpoints in asthma

GSK plc’s interleukin-5 (IL-5) portfolio got boost as depemokimab, an ultra-long-acting biologic targeting IL-5, hit its endpoints in two phase III trials in severe asthma, setting up potential ...
Healio

Benralizumab demonstrates durable remission, low relapse rates in EGPA

Please provide your email address to receive an email when new articles are posted on . The interleukin-5 inhibitor benralizumab yielded durable remission rates in EGPA. The drug showed no new safety ...